Approval · Notice of Compliance 26303 · 2021
AXID: Notice of Compliance 26303
Issued July 21, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26303
- Date
- July 21, 2021
- Company
- Pendopharm Division Of Pharmascience IncMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product¿s labelling material as per the Plain Language Labelling requirements and to update the current Product Monograph (PM) to the 2020 Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AXID | Not yet assigned | — |
Medicinal ingredients
- NIZATIDINE 150 MG per CAP
- NIZATIDINE 300 MG per CAP